Best Test for Screening: MRA or CTA
For a patient with a family history of intracranial aneurysm, order either MRA (magnetic resonance angiography) or CTA (computed tomography angiography) as the initial screening test—both are Class I, Level B recommendations for detection of unruptured intracranial aneurysms. 1
When Screening is Appropriate
Screening is specifically indicated when there are ≥2 first-degree relatives with intracranial aneurysms 1. If only one family member is affected, the decision becomes more nuanced and depends on additional risk factors.
Additional High-Risk Scenarios That Warrant Screening:
- Family history of IA plus autosomal dominant polycystic kidney disease
- Family history of IA plus type IV Ehlers-Danlos syndrome (vascular subtype)
- Coarctation of the aorta or bicuspid aortic valve
- Microcephalic osteodysplastic primordial dwarfism 1
Choosing Between MRA and CTA
Both modalities are equally endorsed by AHA/ASA guidelines 1, but practical considerations guide the choice:
MRA Advantages:
- No radiation exposure (important for repeated screening)
- Sensitivity of 79-89% for aneurysms >3mm 1
- Accuracy of 96-97% with appropriate protocols 1
- Validated in screening studies of high-risk families 2
CTA Advantages:
- Faster acquisition time
- Better for patients with contraindications to MRI
- Excellent spatial resolution
Common pitfall: MRA sensitivity drops significantly for aneurysms <3mm, so negative screening doesn't completely exclude small aneurysms 1.
Follow-Up Strategy
If the initial screen is positive, confirm with digital subtraction angiography (DSA) before making treatment decisions 1. DSA remains the gold standard for surgical/endovascular planning (Class IIa recommendation) 1.
If the initial screen is negative, repeat screening should be considered at 5-10 year intervals because new aneurysms can develop over time 3. The optimal interval remains uncertain, but evidence suggests significant risk of new aneurysm formation within 5 years 3.
Critical Counseling Points Before Screening
Before ordering the test, discuss with the patient:
- Implications for life insurance eligibility
- Psychological burden of detecting an unruptured aneurysm
- Possibility of incidental findings
- That most detected aneurysms are small with low rupture risk
- Treatment carries its own risks (surgical mortality ~5%) 4
Important caveat: Some decision analyses suggest that screening may not reduce overall morbidity/mortality when the prevalence is <10% and surgical risks are factored in 4, 5. However, current guidelines still support screening in the high-risk populations defined above 1.
What NOT to Order
Do not order DSA as the initial screening test—it carries a 0.1% complication risk and should be reserved for confirmation of positive findings or pre-treatment planning 1, 4.